Merck Reports observational Data for Rituximab in Hemophilia B

Merck today announced observational results for rituximab in patients with hemophilia B. The study demonstrated that rituximab achieves high response rates compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia B and support the continued development of rituximab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.